112 related articles for article (PubMed ID: 1465473)
1. Effect of the potassium channel opener EMD 56431 on globally ischemic rat hearts.
Sargent CA; Dzwonczyk S; Grover GJ
Pharmacology; 1992; 45(5):260-8. PubMed ID: 1465473
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
[TBL] [Abstract][Full Text] [Related]
3. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim.
Gross GJ; Mei DA; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1997 Feb; 280(2):533-40. PubMed ID: 9023261
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts.
Jung YS; Moon CH; Cho TS; Yoo SE; Shin HS
Jpn J Pharmacol; 1998 Jan; 76(1):65-73. PubMed ID: 9517406
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Grover GJ; McCullough JR; D'Alonzo AJ; Sargent CA; Atwal KS
J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
[TBL] [Abstract][Full Text] [Related]
7. Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat hearts.
Sargent CA; Wilde MW; Dzwonczyk S; Tuttle JG; Murray HN; Atwal K; Grover GJ
Cardiovasc Res; 1996 Feb; 31(2):270-7. PubMed ID: 8730404
[TBL] [Abstract][Full Text] [Related]
8. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
9. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
[TBL] [Abstract][Full Text] [Related]
11. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects of the cyanoguanidine potassium channel opener P-1075.
Sargent CA; Sleph PG; Dzwonczyk S; Normandin D; Antonaccio MJ; Grover GJ
J Cardiovasc Pharmacol; 1993 Oct; 22(4):564-70. PubMed ID: 7505358
[TBL] [Abstract][Full Text] [Related]
13. Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts.
Grover GJ; Baird AJ; Sleph PG
Cardiovasc Res; 1996 Apr; 31(4):511-7. PubMed ID: 8689642
[TBL] [Abstract][Full Text] [Related]
14. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
[TBL] [Abstract][Full Text] [Related]
15. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
[TBL] [Abstract][Full Text] [Related]
16. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs.
Grover GJ; Sleph PG; Dzwonczyk S
J Cardiovasc Pharmacol; 1990 Dec; 16(6):853-64. PubMed ID: 1704976
[TBL] [Abstract][Full Text] [Related]
18. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB
J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution.
Grover GJ; Sleph PG
J Cardiovasc Pharmacol; 1995 Nov; 26(5):698-706. PubMed ID: 8637183
[TBL] [Abstract][Full Text] [Related]
20. Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines.
Ding CZ; Rovnyak GC; Misra RN; Grover GJ; Miller AV; Ahmed SZ; Kelly Y; Normandin DE; Sleph PG; Atwal KS
J Med Chem; 1999 Sep; 42(18):3711-7. PubMed ID: 10479302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]